These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 33947195)

  • 1. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
    Moreno Márquez C; Fernández Álvarez P; Valdés Delgado T; Castro Laria L; Argüelles Arias F; Caunedo Álvarez Á; Gómez Rodríguez BJ
    Rev Esp Enferm Dig; 2022 Feb; 114(2):89-95. PubMed ID: 33947195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
    Ismail NI; Nawawi KNM; Hsin DCC; Hao KW; Mahmood NRKN; Chearn GLC; Wong Z; Tamil AM; Joseph H; Raja Ali RA
    Helicobacter; 2023 Dec; 28(6):e13017. PubMed ID: 37614081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
    Naghibzadeh N; Salmani F; Nomiri S; Tavakoli T
    BMC Gastroenterol; 2022 Mar; 22(1):107. PubMed ID: 35255819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
    Poonyam P; Chotivitayatarakorn P; Vilaichone RK
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study.
    Francavilla R; Polimeno L; Demichina A; Maurogiovanni G; Principi B; Scaccianoce G; Ierardi E; Russo F; Riezzo G; Di Leo A; Cavallo L; Francavilla A; Versalovic J
    J Clin Gastroenterol; 2014; 48(5):407-13. PubMed ID: 24296423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
    Dore MP; Bibbò S; Loria M; Salis R; Manca A; Pes GM; Graham DY
    Helicobacter; 2019 Dec; 24(6):e12659. PubMed ID: 31502382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metagenomic Changes of Gut Microbiota following Treatment of
    Dore MP; Sau R; Niolu C; Abbondio M; Tanca A; Bibbò S; Loria M; Pes GM; Uzzau S
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
    Yang C; Liang L; Lv P; Liu L; Wang S; Wang Z; Chen Y
    Helicobacter; 2021 Dec; 26(6):e12856. PubMed ID: 34628695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomized, placebo controlled, double-blind study.
    Veldhuyzen Van Zanten S; Farley A; Marcon N; Lahaie R; Archambault A; Hunt R; Bailey R; Owen D; Spénard J; Stiglick A; Aimola N; Colin P
    Can J Gastroenterol; 2000; 14(7):599-602. PubMed ID: 10978947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial.
    Lionetti E; Miniello VL; Castellaneta SP; Magistá AM; de Canio A; Maurogiovanni G; Ierardi E; Cavallo L; Francavilla R
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1461-8. PubMed ID: 17032283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactobacillus ruteri compared with placebo as an adjuvant in quadruple therapy for Helicobacter pylori eradication: A randomized, double-blind, controlled trial.
    Mohtasham M; Joukar F; Maroufizadeh S; Mojtahedi K; Asgharnezhad M; Mansour-Ghanaei F
    Arab J Gastroenterol; 2023 Feb; 24(1):40-44. PubMed ID: 36372695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
    PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
    Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
    Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates.
    Viazis N; Argyriou K; Kotzampassi K; Christodoulou DK; Apostolopoulos P; Georgopoulos SD; Liatsos C; Giouleme O; Koustenis K; Veretanos C; Stogiannou D; Moutzoukis M; Poutakidis C; Mylonas II; Tseti I; Mantzaris GJ
    Nutrients; 2022 Feb; 14(3):. PubMed ID: 35276991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial.
    McNicholl AG; Molina-Infante J; Lucendo AJ; Calleja JL; Pérez-Aisa Á; Modolell I; Aldeguer X; Calafat M; Comino L; Ramas M; Callejo Á; Badiola C; Serra J; Gisbert JP
    Helicobacter; 2018 Oct; 23(5):e12529. PubMed ID: 30141228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
    Navarro-Rodriguez T; Silva FM; Barbuti RC; Mattar R; Moraes-Filho JP; de Oliveira MN; Bogsan CS; Chinzon D; Eisig JN
    BMC Gastroenterol; 2013 Mar; 13():56. PubMed ID: 23530767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study.
    Shavakhi A; Tabesh E; Yaghoutkar A; Hashemi H; Tabesh F; Khodadoostan M; Minakari M; Shavakhi S; Gholamrezaei A
    Helicobacter; 2013 Aug; 18(4):280-4. PubMed ID: 23433200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.